BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Plosker GL, Lyseng-williamson KA. Adalimumab: In Crohn??s Disease. BioDrugs 2007;21:125-32. [DOI: 10.2165/00063030-200721020-00007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
2 Burness CB, Deeks ED. Adalimumab: In Non-Radiographic Axial Spondyloarthritis. Drugs 2012;72:2385-95. [DOI: 10.2165/11470250-000000000-00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
3 Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27:609-621. [PMID: 19663531 DOI: 10.2165/11312710-000000000-00000] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
4 Zhu Z, Dimitrov DS. Construction of a large naïve human phage-displayed Fab library through one-step cloning. Methods Mol Biol 2009;525:129-42, xv. [PMID: 19252833 DOI: 10.1007/978-1-59745-554-1_6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
5 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
6 Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008;2:763-777. [PMID: 19707457 DOI: 10.2147/btt.s3292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
7 Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol 2011;4:139-41. [PMID: 22279403 DOI: 10.4103/0974-620X.91271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Herrero-Morant A, Álvarez-Reguera C, Martín-Varillas JL, Calvo-Río V, Casado A, Prieto-Peña D, Atienza-Mateo B, Maiz-Alonso O, Blanco A, Vicente E, Rúa-Figueroa Í, Cáceres-Martin L, García-Serrano JL, Callejas-Rubio JL, Ortego-Centeno N, Narváez J, Romero-Yuste S, Sánchez J, Estrada P, Demetrio-Pablo R, Martínez-López D, Castañeda S, Hernández JL, González-Gay MÁ, Blanco R. Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. J Clin Med 2020;9:E2608. [PMID: 32796717 DOI: 10.3390/jcm9082608] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Rocha C, Afonso J, Lago P, Arroja B, Vieira AI, Dias CC, Magro F. Accuracy of the new rapid test for monitoring adalimumab levels. Therap Adv Gastroenterol 2019;12:1756284819828238. [PMID: 30833984 DOI: 10.1177/1756284819828238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Luis Cabriada J, García Sánchez V, Gomollón F, Hinojosa J, San Román AL, Luis Mendoza J, Mínguez M, Ricart E, Saro C. Recomendaciones de actuación en pacientes con enfermedad de Crohn que empiezan tratamiento con adalimumab: una guía rápida. Gastroenterología y Hepatología 2008;31:693-7. [DOI: 10.1016/s0210-5705(08)75817-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
11 Brakenhoff LK, van der Heijde DM, Hommes DW, Huizinga TW, Fidder HH. The joint-gut axis in inflammatory bowel diseases. J Crohns Colitis. 2010;4:257-268. [PMID: 21122514 DOI: 10.1016/j.crohns.2009.11.005] [Cited by in Crossref: 74] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
12 Veerappan SG, O’Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:1261-1272. [PMID: 21521250 DOI: 10.1111/j.1365-2036.2011.04667.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
13 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
14 O’Donnell S, O’Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther. 2008;27:885-894. [PMID: 18284649 DOI: 10.1111/j.1365-2036.2008.03648.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
15 Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499. [PMID: 18848553 DOI: 10.1053/j.gastro.2008.07.069] [Cited by in Crossref: 248] [Cited by in F6Publishing: 226] [Article Influence: 17.7] [Reference Citation Analysis]
16 Vo HD, Xu J, Rabinowitz SS, Fisher SE, Schwarz SM. The Liver in Pediatric Gastrointestinal Disease. Journal of Pediatric Gastroenterology & Nutrition 2014;59:288-99. [DOI: 10.1097/mpg.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nahon S, Cadranel J, Chazouilleres O, Biour M, Jouannaud V, Marteau P. Liver and inflammatory bowel disease. Gastroentérologie Clinique et Biologique 2009;33:370-81. [DOI: 10.1016/j.gcb.2009.02.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
18 Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010;18:226-32. [PMID: 20482404 DOI: 10.3109/09273948.2010.483314] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
19 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Borrás-Blasco J, Gracia-Pérez A, Rosique-Robles JD, Casterá MD, Abad FJ. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther 2010;10:301-7. [PMID: 20059372 DOI: 10.1517/14712590903530633] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
21 Burness CB, Keating GM. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis. BioDrugs 2013;27:247-62. [PMID: 23580096 DOI: 10.1007/s40259-013-0033-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
22 Billioud V, Laharie D, Filippi J, Roblin X, Oussalah A, Chevaux J, Hébuterne X, Bigard M, Peyrin-biroulet L. Adherence to adalimumab therapy in Crohnʼs disease: A French multicenter experience: . Inflammatory Bowel Diseases 2011;17:152-9. [DOI: 10.1002/ibd.21491] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
23 Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber S. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00252-1. [PMID: 34388360 DOI: 10.1016/S2468-1253(21)00252-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fehér J, Lengyel G. [Effectiveness and safety of biological therapy with adalimumab]. Orv Hetil 2009;150:1215-22. [PMID: 19546078 DOI: 10.1556/OH.2009.28681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]